New Hope for Geographic Atrophy: An Expert Discussion of Key Practice Changes
This activity is supported by educational grants from Heidelberg Engineering Inc. and Iveric Bio, Inc.
Overview
Release Date: March 28, 2024
Expiration Date: March 29, 2025
Time to Complete Activity: 1.0 hour
Faculty
Arshad M. Khanani, MD, MA, FASRS (Chair)
Clinical Professor
University of Nevada, Reno School of Medicine
Managing Partner, Director of Clinical Research, Director of Fellowship
Sierra Eye Associates
Reno, NV
Carl Danzig, MD
Director of Vitreoretinal Services and Retina Clinical Research
Rand Eye Institute
Deerfield Beach, FL
Affiliate Assistant Professor of Clinical Biomedical Science
Florida Atlantic University
Charles E. Schmidt College of Medicine
Boca Raton, FL
Priya S. Vakharia, MD
Retina Vitreous Associates of Florida
Palm Harbor, FL
Target Audience
This activity is designed to meet the educational needs of retina specialists. It will also be of interest to other eye care providers who are involved in the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), including optometrists, comprehensive ophthalmologists, and their clinical teams.
Educational Provider
This activity is provided by Paradigm Medical Communications, LLC. 
In collaboration with Prevent Blindness. 
Supporter Acknowledgment
This activity is supported by educational grants from Heidelberg Engineering Inc. and Iveric Bio, Inc.
Program Overview
First-ever treatments for GA offer hope in the battle against this relentlessly progressive retinal disease. In this roundtable-style educational activity, expert retina specialists will review best practices in GA diagnosis and deliberate new conundrums that have arisen about whether, when, and how to initiate GA treatment in eligible patients given the recent availability of new agents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify conversion from intermediate dry AMD to GA on imaging
- Recognize patients who are likely to have a fast rate of GA lesion growth
- Describe the role of the complement system in GA pathophysiology, including the differences in the targets of available complement inhibitors
- Differentiate between available GA treatments based on their clinical profiles
- Demonstrate appropriate use of novel therapy for GA treatment, such as patient selection and timing of initiation
Physician Accreditation Statement
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
Instructions for Participation
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the preassessment
- View the online activity in its entirety
- Complete and submit the online postassessment and evaluation. You must answer 70% of the postassessment questions correctly to earn credit. You will have unlimited opportunities to successfully complete the postassessment
A certificate of participation will be available for download/printing immediately following your successful completion of the postassessment and evaluation.
For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
There are no fees for participating in this activity.
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.
All relevant relationships are identified and mitigated according to Paradigm policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. Paradigm is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The content of this activity was independently reviewed to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated.
Arshad M. Khanani, MD, MA, FASRS (Chair)
Consultant: 4D Molecular Therapeutics; AbbVie Inc; Adverum Biotechnologies, Inc; Alcon; Amgen Inc; Annexin Pharmaceuticals; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Beacon Therapeutics; Clearside BioMedical; Complement Therapeutics Ltd; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Frontera Therapeutics, Inc.; Genentech, Inc; Gyroscope Therapeutics Limited; i-Lumen Scientific; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Kriya Therapeutics; Nanoscope Therapeutics, Inc; Novartis AG; Ocular Therapeutix, Inc; Oculis; Ocuphire Pharma, Inc; OcuTerra Therapeutics; Olive BioPharma; Opthea; Oxular; Oxurion NV; Perfuse Therapeutics; Ray Therapeutics; RecensMedical Inc; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; Revive Therapeutics; RevOpsis Therapeutics LLC; Sanofi; Stealth BioTherapeutics Inc; Thea Pharma Inc; UNITY Biotechnology; Vanotech; Vial
Speaker’s Bureau: IVERIC bio, Inc
Research Funding: 4D Molecular Therapeutics; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Annexon, Inc; Apellis Pharmaceuticals, Inc; Aviceda Therapeutics; Exegenesis Bio Co; EyePoint Pharmaceuticals, Inc; F. Hoffmann-La Roche AG; Genentech, Inc; Gyroscope Therapeutics Limited; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Neurotech Pharmaceuticals, Inc; Ocular Therapeutix; Oculis; OcuTerra Therapeutics; Opthea; Oxular; Oxurion NV; REGENXBIO Inc; Vanotech; UNITY Biotechnology
Stocks: Aviceda Therapeutics; Oculis; Opthea; Perfuse Therapeutics; PolyPhotonix Medical Ltd; RecensMedical, Inc; RevOpsis Therapeutics; Vial
Carl Danzig, MD
Advisor: AbbVie Inc; Adverum Biotechnologies, Inc; Genentech, Inc.; IVERIC bio, Inc.
Consultant: Adverum Biotechnologies, Inc; F. Hoffmann-La Roche AG; Genentech, Inc.; IVERIC bio, Inc.; Kodiak Sciences Inc; Regeneron Pharmaceuticals Inc
Speakers’ Bureau: AbbVie Inc; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Bayer Corporation; Cognition Therapeutics; CURACLE Co, LTD; F. Hoffmann-La Roche AG; Genentech, Inc.; Gyroscope Therapeutics Limited; IVERIC bio, Inc.; Kodiak Sciences Inc; Novartis AG; Regeneron Pharmaceuticals Inc; Rezolute, Inc.; UNITY Biotechnolgy
Research Funding: AbbVie Inc; Adverum Biotechnologies, Inc; Alexion Pharmaceuticals, Inc; Cognition Therapeutics; CURACLE Co, LTD; F. Hoffmann-La Roche AG; Genentech, Inc.; Gyroscope Therapeutics Limited; Kodiak Sciences Inc (expired 2023); Novartis AG (expired 2022)
Priya S. Vakharia, MD
Investigator: 4D Molecular Therapeutics; Alexion Pharmaceuticals, Inc; Allgenesis Biotherapeutics Inc.; Annexon, Inc; Aviceda Therapeutics; Bayer Corporation; EyePoint Pharmaceuticals, Inc; Genentech, Inc.; Ionis Pharmaceuticals, Inc; IVERIC bio, Inc; Janssen Pharmaceuticals, Inc; Kodiak Sciences Inc; Novartis AG; Ocular Therapeutix, Inc; OcuTerra Therapeutics; ONL Therapeutics; Opthea; Regeneron Pharmaceuticals Inc; REGENXBIO Inc; UNITY Biotechnology
Consultant: Alimeria Sciences; Apellis Pharmaceuticals, Inc; Bausch & Lomb; Coherus BioSciences; EyePoint Pharmaceuticals, Inc; IVERIC bio, Inc; Notal Vision, Inc.; Novartis AG; Ocuphire Pharma, Inc; Regeneron Pharmaceuticals Inc
Speakers’ Bureau: Apellis Pharmaceuticals, Inc; Bausch & Lomb; Genentech, Inc.; Heidelberg Engineering Inc; IVERIC bio, Inc; Regeneron Pharmaceuticals Inc
Stocks: Network Eye; PRISM Vision Group
Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.
Independent peer reviewer has no relevant financial relationships with ineligible companies to disclose to.
Peer Reviewer Stocks: F. Hoffmann-La Roche Ltd (expired 3/24); Medtronic (expired 3/24); Pfizer Inc. (expired 3/24)
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC must ensure that its activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2024 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.